Fusion Pharmaceuticals, part of the AstraZeneca Group, is redefining precision oncology with nextgeneration radioconjugates that deliver powerful alpha-emitting payloads directly to tumors. Our pipeline spans multiple first-in-class programs backed by a GMP-compliant, brand-new radiopharmaceutical facility in Hamilton. We are turning groundbreaking science into real-world impact for patients. Join us at the forefront of radiopharma innovation and be part of turning breakthrough science into meaningful outcomes for patients. Come build what’s next with us!